Camarri E, Fici F, Marcolongo R
Int J Clin Pharmacol Biopharm. 1978 Nov;16(11):523-6.
Administration of chenodeoxycholic acid (CDCA) to patients with primary hypertriglyceridemia caused the diminution of serum triglyceride concentrations of 54.31% and 46.04% at dosages of 500 mg/day and of 250 mg/day, respectively. Results after 1 month of treatment with 250 mg/day are not statistically different from those obtained with 500 mg/day. Administration of CDCA did not change the serum cholesterol, SGOT, SGPT, total bilirubin, gammaGT or alkaline phosphatase levels.
对原发性高甘油三酯血症患者给予鹅去氧胆酸(CDCA),剂量为500毫克/天和250毫克/天时,血清甘油三酯浓度分别降低了54.31%和46.04%。250毫克/天治疗1个月后的结果与500毫克/天治疗的结果在统计学上无差异。给予CDCA未改变血清胆固醇、谷草转氨酶、谷丙转氨酶、总胆红素、γ-谷氨酰转肽酶或碱性磷酸酶水平。